Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cross Country Healthcare (CCRN) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Cross Country Healthcare (CCRN) over the last 16 years, with Q3 2025 value amounting to $2.2 million.

  • Cross Country Healthcare's Capital Expenditures rose 9492.88% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.6 million, marking a year-over-year decrease of 533.23%. This contributed to the annual value of $8.7 million for FY2024, which is 3764.13% down from last year.
  • Latest data reveals that Cross Country Healthcare reported Capital Expenditures of $2.2 million as of Q3 2025, which was up 9492.88% from $2.0 million recorded in Q2 2025.
  • Cross Country Healthcare's Capital Expenditures' 5-year high stood at $4.0 million during Q2 2023, with a 5-year trough of $1.1 million in Q3 2024.
  • For the 5-year period, Cross Country Healthcare's Capital Expenditures averaged around $2.4 million, with its median value being $2.2 million (2025).
  • In the last 5 years, Cross Country Healthcare's Capital Expenditures surged by 13849.37% in 2021 and then tumbled by 6718.25% in 2024.
  • Over the past 5 years, Cross Country Healthcare's Capital Expenditures (Quarter) stood at $2.3 million in 2021, then fell by 11.27% to $2.0 million in 2022, then skyrocketed by 42.12% to $2.9 million in 2023, then fell by 11.97% to $2.5 million in 2024, then dropped by 13.43% to $2.2 million in 2025.
  • Its Capital Expenditures was $2.2 million in Q3 2025, compared to $2.0 million in Q2 2025 and $1.9 million in Q1 2025.